IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v71y2005i2p181-193.html
   My bibliography  Save this article

Drug coverage in Canada: who is at risk?

Author

Listed:
  • Kapur, Vishnu
  • Basu, Kisalaya

Abstract

No abstract is available for this item.

Suggested Citation

  • Kapur, Vishnu & Basu, Kisalaya, 2005. "Drug coverage in Canada: who is at risk?," Health Policy, Elsevier, vol. 71(2), pages 181-193, February.
    • Handle: RePEc:eee:hepoli:v:71:y:2005:i:2:p:181-193
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(04)00179-4
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Leibowitz, Arleen & Manning, Willard G. & Newhouse, Joseph P., 1985. "The demand for prescription drugs as a function of cost-sharing," Social Science & Medicine, Elsevier, vol. 21(10), pages 1063-1069, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Wang, Chao & Li, Qing & Sweetman, Arthur & Hurley, Jeremiah, 2015. "Mandatory universal drug plan, access to health care and health: Evidence from Canada," Journal of Health Economics, Elsevier, vol. 44(C), pages 80-96.
    2. Sara Allin & Jeremiah Hurley, 2009. "Inequity in publicly funded physician care: what is the role of private prescription drug insurance?," Health Economics, John Wiley & Sons, Ltd., vol. 18(10), pages 1218-1232, October.
    3. Dahlia Balaban & Irfan Dhalla & Michael Law & Chaim Bell, 2013. "Private Expenditures on Brand Name Prescription Drugs after Generic Entry," Applied Health Economics and Health Policy, Springer, vol. 11(5), pages 523-529, October.
    4. Sam Caldbick & Xiaojing Wu & Tom Lynch & Naser Al-Khatib & Mustafa Andkhoie & Marwa Farag, 2015. "The financial burden of out of pocket prescription drug expenses in Canada," International Journal of Health Economics and Management, Springer, vol. 15(3), pages 329-338, September.
    5. Daw, Jamie R. & Morgan, Steven G. & Thomson, Paige A. & Law, Michael R., 2013. "Here today, gone tomorrow: The issue attention cycle and national print media coverage of prescription drug financing in Canada," Health Policy, Elsevier, vol. 110(1), pages 67-75.
    6. Hanley, Gillian E. & Morgan, Steve & Barer, Morris & Reid, Robert J., 2011. "The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada," Health Policy, Elsevier, vol. 101(2), pages 185-194, July.
    7. Guo, Elaine Xiaoyu & Sweetman, Arthur & Guindon, G. Emmanuel, 2020. "Socioeconomic differences in prescription drug supplemental coverage in Canada: A repeated cross-sectional study," Health Policy, Elsevier, vol. 124(3), pages 252-260.
    8. Sarma, Sisira & Basu, Kisalaya & Gupta, Anil, 2007. "The influence of prescription drug insurance on psychotropic and non-psychotropic drug utilization in Canada," Social Science & Medicine, Elsevier, vol. 65(12), pages 2553-2565, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Lundberg, Lena & Johannesson, Magnus & Isacson, Dag G. L. & Borgquist, Lars, 1998. "Effects of user charges on the use of prescription medicines in different socio-economic groups," Health Policy, Elsevier, vol. 44(2), pages 123-134, May.
    2. Crown William H. & Berndt Ernst R. & Baser Onur & Finkelstein Stan N. & Witt Whitney P. & Maguire Jonathan & Haver Kenan E., 2004. "Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter?," Forum for Health Economics & Policy, De Gruyter, vol. 7(1), pages 1-35, January.
    3. Alan, Sule & Crossley, Thomas F. & Grootendorst, Paul & Veall, Michael R., 2002. "The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada," Journal of Health Economics, Elsevier, vol. 21(5), pages 805-826, September.
    4. Yen, Steven T., 2003. "Estimating Demand For Cigarettes And Alcohol With Zero Observations:," 2003 Annual meeting, July 27-30, Montreal, Canada 22168, American Agricultural Economics Association (New Name 2008: Agricultural and Applied Economics Association).
    5. Li, M. & Ohkusa, Y., 2000. "An Empirical Research of Substitutability between Medical Services and Over-the-Counter Medication. An Analysis of Thirteen Different Minor Ailments," ISER Discussion Paper 0522, Institute of Social and Economic Research, Osaka University.
    6. Bakker, F. M. & van Vliet, R. C. J. A., 1995. "The introduction of deductibles for prescription drugs in a national health insurance: compulsory or voluntary?," Health Policy, Elsevier, vol. 31(1), pages 53-65, January.
    7. Dalen, Dag Morten & Sorisio, Enrico & Strøm, Steinar, 2009. "Choosing among Competing Blockbusters: Does the Identity of the Third-party Payer Matter for Prescribing Doctors?," Memorandum 10/2009, Oslo University, Department of Economics.
    8. Guido Citoni, 2015. "On the inverse relationship between ex-ante and ex-post moral hazard: the case of smokers," Working Papers CEB 15-041, ULB -- Universite Libre de Bruxelles.
    9. Paul Grootendorst & Mitchell Levine, 2002. "Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population," Quantitative Studies in Economics and Population Research Reports 372, McMaster University.
    10. Sarma, Sisira & Basu, Kisalaya & Gupta, Anil, 2007. "The influence of prescription drug insurance on psychotropic and non-psychotropic drug utilization in Canada," Social Science & Medicine, Elsevier, vol. 65(12), pages 2553-2565, December.
    11. Ii, Masako & Ohkusa, Yasushi, 2002. "Should the Coinsurance Rate Be Increased in the Case of the Common Cold? An Analysis Based on an Original Survey," Journal of the Japanese and International Economies, Elsevier, vol. 16(3), pages 353-371, September.
    12. Danzon, Patricia M. & Chao, Li-Wei, 2000. "Cross-national price differences for pharmaceuticals: how large, and why?," Journal of Health Economics, Elsevier, vol. 19(2), pages 159-195, March.
    13. Marin C. Gemmill & Joan Costa‐Font & Alistair McGuire, 2007. "In search of a corrected prescription drug Elasticity estimate: a meta‐regression approach," Health Economics, John Wiley & Sons, Ltd., vol. 16(6), pages 627-643, June.
    14. Brekke, Kurt R. & Grasdal, Astrid L. & Holms, Tor Helge, 2009. "Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?," European Economic Review, Elsevier, vol. 53(2), pages 170-185, February.
    15. Dalen Dag Morten & Locatelli Marilena & Sorisio Enrico & Strom Steinar, 2011. "A Probability Approach to Pharmaceutical Demand and Price Setting: Does the Identity of the Third-Party Payer Matters for Prescribing Doctors?," Department of Economics and Statistics Cognetti de Martiis. Working Papers 201110, University of Turin.
    16. Lagarde, Mylène & Blaauw, Duane, 2022. "Overtreatment and benevolent provider moral hazard: Evidence from South African doctors," Journal of Development Economics, Elsevier, vol. 158(C).
    17. Granlund, David, 2012. "The effect of pharmacies’ right to negotiate discounts on the market share of parallel imported pharmaceuticals," HUI Working Papers 75, HUI Research.
    18. Doran, Evan & Robertson, Jane & Henry, David, 2005. "Moral hazard and prescription medicine use in Australia--the patient perspective," Social Science & Medicine, Elsevier, vol. 60(7), pages 1437-1443, April.
    19. Arcidiacono, Peter & Ellickson, Paul B. & Landry, Peter & Ridley, David B., 2013. "Pharmaceutical followers," International Journal of Industrial Organization, Elsevier, vol. 31(5), pages 538-553.
    20. Jan Zápal, 2010. "Doctor-Visit Co-Payment Exemption for Children: First Look at the Data," Czech Journal of Economics and Finance (Finance a uver), Charles University Prague, Faculty of Social Sciences, vol. 60(1), pages 58-72, February.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:71:y:2005:i:2:p:181-193. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.